J&J plans to sell LifeScan for $2.1bn
Johnson & Johnson (J&J) has revealed plans to sell LifeScan, its blood glucose monitoring unit, for $2.1 billion.
Private investment firm Platinum Equity has put in a binding offer for the unit, according to a press release published on Friday, March 16. If the offer is accepted, the transaction would be expected to close by the end of 2018.
LifeScan’s net revenue for 2017 was approximately $1.5 billion. Its OneTouch blood glucose monitoring products are used by millions worldwide.
Ashley McEvoy, company group chairman, consumer medical devices at J&J, said: “This initiative is part of our ongoing, disciplined approach to portfolio management to focus on our most promising opportunities to help patients and drive growth.”
J&J will continue to serve those impacted by diabetes in areas such as bariatric surgery and through medicines such as Invokana (canagliflozin) and Invokamet (canagliflozin/metformin HCl).
Last month, LSIPR reported that J&J planned to strengthen its medical device capabilities with the acquisition of French medical technology company Orthotax.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
Join us at LSPN North America on April 26, find out more here.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk